<DOC>
	<DOCNO>NCT01396005</DOCNO>
	<brief_summary>In study , participant methadone buprenorphine/naloxone maintenance therapy give boceprevir . Blood sample take specified interval find whether boceprevir affect pharmacokinetics methadone , buprenorphine , naloxone .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetic Effect SCH 503034 ( Boceprevir ) Methadone Buprenorphine/Naloxone Plasma Concentrations ( P08123 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>Body Mass Index ( BMI ) 18 36 , inclusive Reliable participation methadone maintenance buprenorphine maintenance buprenorphine/naloxone maintenance program least two ( 2 ) month prior Day 1 . Is receive daily oral dose methadone therapy stable individualize dose least 4 week , receive daily buprenorphine dose stable individualize dose 4 week , buprenorphine therapy , naloxone add least 2 week prior Day 1 . 12lead electrocardiogram ( ECG ) conduction interval within genderspecific normal range Vital sign within normal range Clinical laboratory test within normal range Women postmenopausal , surgically sterilize , premenopausal use medicallyaccepted method contraception . Pregnancy , breast feeding , intention become pregnant father child study within 3 month end trial History presence inflammatory bowel disease , ulcer , gastrointestinal rectal bleed History major gastrointestinal tract surgery gastrectomy , gastroenterostomy , bowel resection History pancreatic injury pancreatitis History presence liver disease liver injury History presence impair renal function History urinary obstruction difficulty void History infectious disease within 4 week prior drug administration opinion investigator , affect subject 's ability participate trial Positive hepatitis B surface antigen , hepatitis C antibodies human immunodeficiency virus ( HIV ) Positive screen drug high potential abuse cocaine , amphetamine , methylenedioxymethamphetamine ( MDMA ) , barbiturates , benzodiazepine , opiates/opioids Excessive use alcohol 2 week prior Day 1 , define great 3 glass alcoholic beverage ( 1 approximately equivalent : beer [ 284 mL/10 oz ] , wine [ 125 mL/4 oz ] , distil spirit [ 25 mL/1 oz ] ) per day . Blood donation past 60 day Previous administration SCH 503034 ( boceprevir ) Current participation another clinical study participation clinical study ( e.g. , laboratory clinical evaluation ) within 30 day baseline Study staff personnel family member study staff personnel Demonstrated allergic reaction ( eg , food , drug , atopic reaction asthmatic episode ) , opinion investigator sponsor , interfere ability participate trial History malignancy within 5 year Screening Consumption excessive amount ( equivalent &gt; 6 cup brew coffee/day ) coffee , tea , cola caffeinated beverage Receipt follow recently washout period prior Baseline : inhibitor inducer cytochrome ( CYP ) P450 , CYP2B6 , CYP3A4 , CYP2D6 ; oral contraceptive contain drospirenone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>